Literature DB >> 21726474

Diabetes: treating hypertension.

Sandeep Vijan1.   

Abstract

INTRODUCTION: Among people with diabetes, about 40% of those aged 45 years, and more than 60% of those aged 75 years and over, will have a blood pressure over 140/90 mmHg. Major cardiac events occur in approximately 5% of people with diabetes and untreated hypertension each year, and the risk is higher in those with other risk factors, such as diabetic nephropathy. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of antihypertensives in people with diabetes and hypertension? What are the effects of different blood pressure targets in people with diabetes and hypertension? We searched: Medline, Embase, The Cochrane Library, and other important databases up to February 2009 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 22 systematic reviews, RCTs, or observational studies that met our inclusion criteria.
CONCLUSIONS: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: alpha-blockers; angiotensin II receptor antagonists; angiotensin-converting enzyme (ACE) inhibitors; beta-blockers; blood pressure targets (lower or higher); calcium-channel blockers; and diuretics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 21726474      PMCID: PMC2907833     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  29 in total

1.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Authors:  Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

2.  Clinical Practice Recommendations 2005.

Authors: 
Journal:  Diabetes Care       Date:  2005-01       Impact factor: 19.112

Review 3.  Antihypertensive agents for primary prevention of diabetic nephropathy.

Authors:  Giovanni F M Strippoli; Maria Craig; Francesco P Schena; Jonathan C Craig
Journal:  J Am Soc Nephrol       Date:  2005-08-31       Impact factor: 10.121

Review 4.  Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression.

Authors:  Giovanni F M Strippoli; Maria C Craig; Francesco P Schena; Jonathan C Craig
Journal:  J Am Soc Nephrol       Date:  2006-04       Impact factor: 10.121

5.  Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators.

Authors:  J Tuomilehto; D Rastenyte; W H Birkenhäger; L Thijs; R Antikainen; C J Bulpitt; A E Fletcher; F Forette; A Goldhaber; P Palatini; C Sarti; R Fagard
Journal:  N Engl J Med       Date:  1999-03-04       Impact factor: 91.245

6.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

Authors: 
Journal:  BMJ       Date:  1998-09-12

7.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

Authors: 
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

8.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

9.  Preventing microalbuminuria in type 2 diabetes.

Authors:  Piero Ruggenenti; Anna Fassi; Anelja Parvanova Ilieva; Simona Bruno; Ilian Petrov Iliev; Varusca Brusegan; Nadia Rubis; Giulia Gherardi; Federica Arnoldi; Maria Ganeva; Bogdan Ene-Iordache; Flavio Gaspari; Annalisa Perna; Antonio Bossi; Roberto Trevisan; Alessandro R Dodesini; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2004-10-31       Impact factor: 91.245

10.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.